



**Canadian  
Cardiovascular  
Society**

**MYCOVACC**

The CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) is a multi-centre, pan-Canadian study funded by the Public Health Agency of Canada.

## Your input matters! Complete the MYCOVACC Survey

The CCS requests your participation in a survey to guide the MYCOVACC national surveillance study. The 15-minute survey asks questions about the study methodology, communications, and knowledge translation priorities. The survey closes on **March 23, 2023**.

Please share the survey link with your colleagues to help inform our work on post-vaccine myopericarditis.

[Click here to complete](#)

## Meet the MYCOVACC team

MYCOVACC is a collaborative project involving research and public health partners from across Canada. We are excited to welcome the Canadian Congenital and Pediatric Cardiology Research Network as a project partner.

In this issue, we profile two team members:

### **Dr. Tahir Kafil MD, FRCPC, MYCOVACC Steering Committee Member**



Tahir Kafil completed his Internal Medicine Residency and Adult Cardiology Fellowship at Western University. He subsequently completed his Advanced Heart Failure and Cardiac Transplantation Fellowship at the University of Ottawa Heart Institute. During his time in Ottawa, he helped establish the Post-Vaccine Myopericarditis Clinic. He is a co-investigator in the CIHR-funded COVID-VIHRP study. For his research work, he was awarded the prestigious Myocarditis Foundation's Fellowship Grant. He is presently pursuing further training in Echocardiography and Advanced Cardiac Imaging at the Cleveland Clinic Foundation in Ohio, USA.

### **Dr. Michael Houry MD, FRCPC, MYCOVACC Steering Committee**

## Member

Michael Khoury is a pediatric cardiologist and Assistant Professor at the Stollery Children's Hospital, University of Alberta. He completed his pediatric residency at the University of Toronto and pediatric cardiology fellowship at the University of Toronto and Alberta. He underwent subspecialty fellowships in Pediatric Preventive Cardiology at Cincinnati Children's Hospital Medical Center (CCHMC) and Advanced Heart Failure and Transplantation at CCHMC and University of Alberta. He is a co-lead of the Kawasaki Disease/MIS-C/mRNA vaccine-associated myocarditis clinic at the University of Alberta.



---

## Become a MYCOVACC study site

The CCS is actively recruiting cardiac care centres, cardiology clinics and cardiologists from across Canada to contribute to the study. [Learn more.](#)

---

## Stakeholder consultation interviews: Have your say!



The CCS is consulting with the cardiovascular community about the study methodology, communications, and knowledge translation priorities. To participate in a focus group or individual interview, contact Meredith Wright at [mycovacc@ccs.ca](mailto:mycovacc@ccs.ca).

---

## MYCOVACC seeks patient advisors

The CCS is looking for patients and carers with first-hand experience with post-vaccine myocarditis and/or pericarditis to join MYCOVACC committees. The MYCOVACC team is also seeking patient advisors to share their ideas in stakeholder consultation interviews. For information, contact Meredith Wright at [mycovacc@ccs.ca](mailto:mycovacc@ccs.ca)

---

## Watch: Canadian Cardiovascular Society Leading a Renaissance in Myocarditis Research and Policy

This Canadian Cardiovascular Congress 2022 session introduces MYCOVACC to the Canadian cardiovascular community. Dr. Peter Liu and Dr. Sean Virani chair the session. The presenters are Dr. Tahir Kafil, Susanna Ogunnaike-Cooke, Carolyn Pullen, and Dr. Nat Hawkins.



The presentation:

- Reviews diagnostic criteria for vaccine myocarditis/pericarditis and COVID-19 myocarditis using an illustrative clinical vignette.
- Describes the public health context and pathways for adverse event reporting.
- Explores ways for the cardiovascular community to engage in the project.

[Click here to watch](#)

---

## Recent research

Husby A, Gulseth HL, Hovi P, Hansen JV, Pihlström N, Gunnes N, Härkänen T, Dahl J, Karlstad Ø, Heliö T, & Køber L. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: Population based cohort study. *BMJ Medicine*. 2023 Feb 1;2(1). <http://dx.doi.org/10.1136/bmjmed-2022-000373>

Parhizgar P, Yazdankhah N, Rzepka AM, Chung KY, Ali I, Lai R, Russell V, & Cheung AM. Beyond Acute COVID-19: A Review of Long-Term Cardiovascular Outcomes. *Canadian Journal of Cardiology* (2023). <https://doi.org/10.1016/j.cjca.2023.01.031>

Réa AB, & Luk A. Incident Myocarditis in COVID-19 Recovered Patients: Is there a Cause for Concern? *Canadian Journal of Cardiology* (2023). <https://doi.org/10.1016/j.cjca.2023.01.024>

---

Email: [mycovacc@ccs.ca](mailto:mycovacc@ccs.ca)

Website: <https://ccs.ca/mycovacc/>

*Financial contribution from*



Public Health  
Agency of Canada

Agence de la santé  
publique du Canada



[Please click here to opt out of this mailing or to change your CCS communication preferences.](#)

Canadian Cardiovascular Society | 1000-150 Elgin Street, Ottawa, K2P 1L4 Canada

[Unsubscribe webmaster@ccs.ca](mailto:Unsubscribe.webmaster@ccs.ca)

[Constant Contact Data Notice](#)

Sent by [communications@ccs.ca](mailto:communications@ccs.ca)